JP2016518411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518411A5 JP2016518411A5 JP2016512995A JP2016512995A JP2016518411A5 JP 2016518411 A5 JP2016518411 A5 JP 2016518411A5 JP 2016512995 A JP2016512995 A JP 2016512995A JP 2016512995 A JP2016512995 A JP 2016512995A JP 2016518411 A5 JP2016518411 A5 JP 2016518411A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- amount
- pooled human
- mmse
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940027941 immunoglobulin g Drugs 0.000 claims description 122
- 208000024827 Alzheimer disease Diseases 0.000 claims description 104
- 238000011282 treatment Methods 0.000 claims description 87
- 230000037396 body weight Effects 0.000 claims description 67
- 230000006996 mental state Effects 0.000 claims description 64
- 238000011269 treatment regimen Methods 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 47
- 108700028369 Alleles Proteins 0.000 claims description 44
- 229940098197 human immunoglobulin g Drugs 0.000 claims description 43
- 230000000977 initiatory effect Effects 0.000 claims description 43
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 238000007914 intraventricular administration Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000969 carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 216
- 210000003169 central nervous system Anatomy 0.000 description 18
- 108010003272 Hyaluronate lyase Proteins 0.000 description 6
- 102000001974 Hyaluronidases Human genes 0.000 description 6
- 229960002773 hyaluronidase Drugs 0.000 description 6
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 3
- 101150055528 SPAM1 gene Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361855062P | 2013-05-06 | 2013-05-06 | |
| US61/855,062 | 2013-05-06 | ||
| US201361833447P | 2013-06-10 | 2013-06-10 | |
| US61/833,447 | 2013-06-10 | ||
| US201361844732P | 2013-07-10 | 2013-07-10 | |
| US61/844,732 | 2013-07-10 | ||
| US201361886464P | 2013-10-03 | 2013-10-03 | |
| US61/886,464 | 2013-10-03 | ||
| PCT/US2014/036848 WO2014182631A1 (en) | 2013-05-06 | 2014-05-05 | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518411A JP2016518411A (ja) | 2016-06-23 |
| JP2016518411A5 true JP2016518411A5 (enExample) | 2017-06-15 |
| JP6424210B2 JP6424210B2 (ja) | 2018-11-14 |
Family
ID=50943566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512995A Active JP6424210B2 (ja) | 2013-05-06 | 2014-05-05 | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20140328856A1 (enExample) |
| EP (2) | EP2994160B1 (enExample) |
| JP (1) | JP6424210B2 (enExample) |
| AU (4) | AU2014262890B2 (enExample) |
| DK (1) | DK2994160T3 (enExample) |
| ES (1) | ES2740127T3 (enExample) |
| HR (1) | HRP20191383T1 (enExample) |
| HU (1) | HUE044737T2 (enExample) |
| LT (1) | LT2994160T (enExample) |
| PL (1) | PL2994160T3 (enExample) |
| PT (1) | PT2994160T (enExample) |
| WO (1) | WO2014182631A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4289820A3 (en) | 2014-03-21 | 2024-03-13 | Alzheon, Inc. | Compounds for use in treating alzheimer's disease in apoe4+/+ patients |
| WO2016033382A1 (en) * | 2014-08-27 | 2016-03-03 | Capnia, Inc. | Methods for immune globulin administration |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JP6789579B2 (ja) * | 2015-09-10 | 2020-11-25 | アルジオン， インコーポレイテッド | 特定の患者集団において神経変性障害を処置する方法 |
| CN114019170A (zh) * | 2016-01-20 | 2022-02-08 | 基因泰克公司 | 用于阿尔茨海默氏病的高剂量治疗 |
| HRP20211628T1 (hr) * | 2016-08-18 | 2022-02-04 | Alkahest, Inc. | Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem |
| BR112019022402A2 (pt) * | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
| FI128916B (en) * | 2018-02-05 | 2021-03-15 | Vetcare Oy | Health-promoting composition and method for its preparation |
| KR102276545B1 (ko) * | 2019-09-05 | 2021-07-15 | 고려대학교 산학협력단 | Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치 |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CA3198827A1 (en) * | 2020-10-30 | 2022-05-05 | Rush University Medical Center | Intranasal immunotherapy for the treatment of alzheimer's disease |
| EP4472679A1 (en) * | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (enExample) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| WO2003028668A2 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | Gammaglobulin treatment of immune disorders |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| WO2006091332A2 (en) | 2005-02-23 | 2006-08-31 | Alza Corporation | Intranasal administration of active agents to the central nervous system |
| PL1981540T3 (pl) * | 2006-01-30 | 2013-08-30 | Grifols Therapeutics Inc | Sposób leczenia i profilaktyki chorób związanych z odkładaniem się amyloidu z zastosowaniem IgM |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
| SG184820A1 (en) * | 2010-04-13 | 2012-11-29 | Baxter Int | Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease |
| WO2011142778A1 (en) * | 2010-05-13 | 2011-11-17 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| JP6055412B2 (ja) * | 2010-09-17 | 2016-12-27 | バクスアルタ ゲーエムベーハー | 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化 |
| KR20130139153A (ko) * | 2011-01-18 | 2013-12-20 | 백스터 인터내셔널 인코포레이티드 | 인간 혈액 중 항-베타 아밀로이드 항체의 측정 |
| US20120251524A1 (en) * | 2011-04-01 | 2012-10-04 | Baxter Healthcare S.A. | Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease |
| ES2714999T3 (es) * | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
-
2014
- 2014-05-05 AU AU2014262890A patent/AU2014262890B2/en active Active
- 2014-05-05 EP EP14730660.9A patent/EP2994160B1/en active Active
- 2014-05-05 ES ES14730660T patent/ES2740127T3/es active Active
- 2014-05-05 PL PL14730660T patent/PL2994160T3/pl unknown
- 2014-05-05 WO PCT/US2014/036848 patent/WO2014182631A1/en not_active Ceased
- 2014-05-05 LT LTEP14730660.9T patent/LT2994160T/lt unknown
- 2014-05-05 HR HRP20191383TT patent/HRP20191383T1/hr unknown
- 2014-05-05 US US14/270,192 patent/US20140328856A1/en not_active Abandoned
- 2014-05-05 JP JP2016512995A patent/JP6424210B2/ja active Active
- 2014-05-05 HU HUE14730660 patent/HUE044737T2/hu unknown
- 2014-05-05 EP EP19175106.4A patent/EP3552624A1/en active Pending
- 2014-05-05 DK DK14730660.9T patent/DK2994160T3/da active
- 2014-05-05 PT PT14730660T patent/PT2994160T/pt unknown
-
2019
- 2019-01-14 US US16/247,141 patent/US20190144530A1/en not_active Abandoned
- 2019-04-09 AU AU2019202459A patent/AU2019202459B2/en active Active
-
2020
- 2020-10-19 AU AU2020257034A patent/AU2020257034A1/en not_active Abandoned
-
2021
- 2021-04-19 US US17/234,658 patent/US20210238267A1/en not_active Abandoned
-
2024
- 2024-02-19 AU AU2024201051A patent/AU2024201051A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518411A5 (enExample) | ||
| JP2023089119A (ja) | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 | |
| Jonsson et al. | Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab | |
| EP3478712B1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| ES2656442T3 (es) | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer | |
| JP6424210B2 (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| Seidling et al. | Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events | |
| CN117024583A (zh) | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| EP4218794A3 (en) | Immunological targeting of pathological tau proteins | |
| JP2017507139A5 (enExample) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2016522211A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2024112859A5 (enExample) | ||
| SG10201901242PA (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| Delrieu et al. | Amyloid beta peptide immunotherapy in Alzheimer disease | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| JP2020506162A5 (enExample) | ||
| JP2018534259A5 (enExample) | ||
| JP2018530574A5 (enExample) | ||
| WO2017191327A3 (en) | Her-2 binding antibodies | |
| WO2007096396A3 (en) | Methods for treating autoimmune or demyelinating diseases | |
| WO2008090332A3 (en) | Factor h polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |